Comparative Pharmacology
Head-to-head clinical analysis: PULMOLITE versus TECHNETIUM TC 99M MEDRONATE KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PULMOLITE versus TECHNETIUM TC 99M MEDRONATE KIT.
PULMOLITE vs TECHNETIUM TC-99M MEDRONATE KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
PULMOLITE is a leukotriene receptor antagonist (LTRA) that selectively and competitively inhibits the cysteinyl leukotriene (CysLT1) receptor in the human airway, thereby reducing bronchoconstriction, mucus secretion, and eosinophilic infiltration.
Technetium Tc-99m medronate (MDP) is a bone-seeking radiopharmaceutical that binds to calcium ions in hydroxyapatite crystals of bone. Uptake is proportional to osteoblastic activity and regional blood flow, allowing scintigraphic imaging of skeletal structures.
Adults: 200 mg intravenously every 12 hours over 30 minutes.
Intravenous injection: 370-1110 MBq (10-30 mCi) for bone imaging. Adult dose is administered once for each imaging procedure.
None Documented
None Documented
Terminal elimination half-life: 12 hours (range 10–14 h) in adults with normal renal function (CrCl >90 mL/min); prolonged to 24–30 h in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life: 6.02 hours (range 5.8–6.3 hours) in patients with normal renal function; prolonged in renal impairment.
Primarily renal (80%) as unchanged drug; 15% fecal via biliary excretion; 5% metabolized.
Renal: approximately 50% of injected dose excreted unchanged in urine within 24 hours. Biliary/fecal: less than 5%.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical